Profund Advisors LLC Grows Stake in Recursion Pharmaceuticals, Inc. $RXRX

Posted by Brian Himes on May 21st, 2026

Profund Advisors LLC increased its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 120.9% in the 4th quarter, Holdings Channel reports. The firm owned 356,662 shares of the company’s stock after purchasing an additional 195,207 shares during the period. Profund Advisors LLC’s holdings in Recursion Pharmaceuticals were worth $1,459,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $31,000. Sequoia Financial Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $41,000. Allworth Financial LP raised its holdings in shares of Recursion Pharmaceuticals by 85.6% during the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the last quarter. IFP Advisors Inc lifted its position in shares of Recursion Pharmaceuticals by 81.5% in the third quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after acquiring an additional 4,650 shares in the last quarter. Finally, PFG Investments LLC purchased a new position in shares of Recursion Pharmaceuticals in the third quarter valued at approximately $53,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the subject of several research reports. Bank of America dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. JPMorgan Chase & Co. dropped their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Morgan Stanley increased their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Finally, Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.10.

Check Out Our Latest Stock Report on Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock opened at $2.96 on Thursday. The business’s 50 day moving average price is $3.30 and its 200 day moving average price is $3.93. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -2.47 and a beta of 1.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. During the same period in the prior year, the business earned ($0.50) EPS. The firm’s quarterly revenue was down 56.8% on a year-over-year basis. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.02 EPS for the current year.

Insider Activity

In related news, CFO Ben R. Taylor sold 7,956 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the completion of the sale, the chief financial officer owned 1,180,318 shares of the company’s stock, valued at approximately $4,001,278.02. This represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Najat Khan sold 28,298 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $3.35, for a total transaction of $94,798.30. Following the sale, the chief executive officer owned 2,262,085 shares of the company’s stock, valued at approximately $7,577,984.75. The trade was a 1.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 96,254 shares of company stock valued at $320,369. 8.43% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Company Profile

(Free Report)

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.